Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT05717764 Not yet recruiting - Clinical trials for Recurrent Metastatic Nasopharyngeal Carcinoma

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Start date: February 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, positive-controlled, multicenter Phase ะจ study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.

NCT ID: NCT05622474 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

Start date: November 30, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the efficacy and safety of curative radiotherapy with or without induction chemotherapy in patients with T3N1M0 nasopharyngeal carcinoma. The main question[s] it aims to answer are: - Whether induction chemotherapy confers a survival benefit in patients with T3N1M0 nasopharyngeal carcinoma with high risks factors. - Whether induction chemotherapy worsens adverse effects in patients with T3N1M0 nasopharyngeal carcinoma. Participants in experimental group will receive 3 cycles induction chemotherapy (GP or TPF) followed by concurrent chemoradiotherapy.Participants in control group will receive concurrent chemoradiotherapy only. Researchers will compare FFS, OS and AE or SAE to see if patients can benefit from induction chemotherapy or screen out high-risk factors associated with survival benefits.

NCT ID: NCT05519956 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Start date: September 16, 2022
Phase: Phase 3
Study type: Interventional

Currently, nasopharyngeal carcinoma (NPC) patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II will be recommended to receive level Ib-covering IMRT according to the International Guidelines. Our previous study, which retrospectively analyzed a cohort of 390 patients, indicated that it should be safe and feasible for patients who only had at least one of the above two radiological features. Thus, the investigators conduct this non-inferior phase 3, randomized trial to further determine the feasibility of sparing level Ib in patients who had level II involvement with ECE, and/or had a MAD of greater than 2cm in level II.

NCT ID: NCT05484375 Not yet recruiting - Clinical trials for Metastatic Nasopharyngeal Carcinoma

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Start date: September 2022
Phase: Phase 2
Study type: Interventional

to evaluate the efficacy and safety of toripalimab and capecitabine maintenance therapy in patients with metastatic nasopharyngeal carcinoma (NPC) after first-line gemcitabine/cisplatin combined with toripalimab.

NCT ID: NCT05433597 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC

Start date: July 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Based on the application prospect of rmh-TNF combined with chemotherapy in the treatment of solid tumors. In this study, cisplatin combined with low dose 5-FU was proposed to enhance the immune function of 5-FU. Tianenfu is a novel recombinant modified human tumor necrosis with high activity and low toxicity. The fact that RMH-TNF has the potential of better in vivo efficacy and clinical antitumor effect. Therefore, the study was designed to investigate the treatment of concurrent chemoradiotherapy combined with TNF versus concurrent chemoradiotherapy combined with placebo for the efficacy and safety of advanced nasopharyngeal carcinoma.

NCT ID: NCT05432219 Not yet recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma

Start date: June 2022
Phase: N/A
Study type: Interventional

This is a a prospective, single-arm, and exploratory study of endoscopic resection of recurrent nasopharyngeal carcinoma via transoral retropterygoid approach.

NCT ID: NCT05417139 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP chemotherapy combined with radiotherapy for newly diagnosed metastatic NPC.

NCT ID: NCT05341193 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: April 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment regimen". Considering the synergistic effect among radiotherapy, immunotherapy and anti-angiogenesis therapy, we chose PD-1 inhibitor combined with bevacizumab to replace cisplatin chemotherapy.

NCT ID: NCT05340270 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma.

NCT ID: NCT05330169 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Hearing Toxicity of Nasopharyngeal Carcinoma After Chemoradiotherapy

Start date: July 1, 2022
Phase:
Study type: Observational

This observational cohort study was aimed to evaluate the hearing toxicity at multiple time points from baseline to 1 year after radical chemoradiotherapy among nasopharyngeal carcinoma patients.